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Abstract
Background: Prognostic factors of melanoma with distant metastasis and systemic treatment are only poorly established.
This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in
advanced patients receiving systemic treatment.
Patients and Methods: We analysed overall survival of 499 patients from the university department of dermatology in
Tuebingen, Germany, with unresectable melanoma at the time point of initiation of first-line systemic therapy. Only patients
who started treatment between the years 2000 and 2010 were included. Disease-specific survival was calculated by bivariate
Kaplan Meier survival probabilities and multivariate Cox hazard regression analysis.
Results: In univariate analysis LDH, S100B, the site of distant metastasis (soft tissue vs. lung vs. other visceral), the presence
of brain metastases and the type of treatment (monochemotherapy, polychemotherapy, immunotherapy or
biochemotherapy) were associated with overall survival (all p,0.001). In multivariate analysis LDH (Hazard ratio [HR] 1.6
[1.3–2.1]; p,0.001), S100B (HR 1.6 [1.2–2.1]; p,0.001) and the presence of brain metastases (HR 1.5 [1.1–1.9]; p = 0.009), but
not the type of treatment had significant independent impact. Among those factors normal S100B was the best indicator of
long-term survival, which was 12.3% after 5 years for this subgroup.
Conclusion: Serum S100B is a prognostic marker predicting survival at the time of initiation of first-line treatment in
unresectable melanoma patients. Compared to the other independent factors LDH and the presence of brain metastases it
is most appropriate to predict long-term survival and requires further prospective investigation in patients treated with new
and more potent drugs in metastatic melanoma.
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Introduction
The prognosis of advanced melanoma patients is poor. Long
term survival can be observed after complete metastasectomy of
distant metastases with 5-years survival rates up to 41% [1,2] but is
rarely observed in patients with unresectable disease after systemic
therapies [3]. For decades it was questionable whether the natural
course of disease can be improved by available systemic treatments
at all. Overlapping survival curves were observed in a number of
randomized clinical trials (RCTs) testing different drugs and
clinical responses were only eventually observed. In a meta-
analysis of 41 trials conducted before 2003 the outcome after
systemic therapies was investigated comparing mono-, polyche-
motherapy and immunotherapy, and biochemotherapy. While the
response rate was higher in patients receiving poly- or bio-
chemotherapy regimen, overall survival was not affected according
to the treatment category [4]. Before 2010, an improved overall
survival could not be demonstrated by any systemic drug
treatment in randomized controlled clinical trials (RCTs) and
prognosis of patients with unresectable distant metastases was
mainly defined by the serum lactate dehydrogenase (LDH) and the
localization of distant metastases. Both factors were intensively
studied before start of systemic therapy [5–7]. Based on these
studies LDH was the first serum biomarker to be included in the
American Joint Committee on Cancer (AJCC) staging system for
patients with distant metastases since 2001 in addition to the
pattern of involved organs [8]. Both factors remain the most
important strata in RTCs and are used to classify AJCC stage IV
into the M categories M1a (soft tissue metastasis), M1b (pulmonary
involvement), and M1c (involvement of other visceral organs or
elevated LDH) [9].
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In addition to LDH, S100B is an independent prognostic serum
marker at the time of stage IV diagnosis as reported by us before
and can be useful to select patients for complete metastasect-
omy.[3] However, its value at later time-points, analysing patients
with unresectable disease and increasing tumour-load, remains
inconclusive. Before start of systemic treatment multivariate
analyses comparing S100B and LDH and considering established
clinical data have only been reported in small cohorts with
conflicting results [10–14].
In the present study we investigated prognostic factors in a
retrospective cohort of 499 institutional melanoma patients who
received first-line systemic treatment between 2000 and 2010. The
main aims were (a) to analyse if the type of systemic treatment is
relevant for survival of unselected patients and (b) to clarify the
prognostic impact of the serum marker S100B at the initiation of
first line systemic therapy compared to LDH.
Methods
Ethics statement
All patients had given their written informed consent to have
clinical data recorded by the Central Malignant Melanoma
Registry (CMMR) registry. The institutional ethics committee
Tu¨bingen approved the study (ethic vote 449/2013R).
Patients
Patients from the university department of dermatology in
Tuebingen, Germany, with cutaneous or unknown primary
melanoma and distant metastasis were identified in the Central
Malignant Melanoma Registry (CMMR) database which prospec-
tively records patients from more than 60 dermatological centres
in Germany. Next, those with the first systemic treatment for non-
resectable melanoma initiated between 2000 and 2010, and
available follow-up data were selected, resulting in a final sample
size of 499 after individual file review. All patients had given their
written informed consent to have their data recorded by the
CMMR. The aims and methods of data collection by the CMMR
have previously been reported in detail [15].
Data obtained for each patient included gender, the date of the
last follow-up, and the date and cause of death, if applicable. The
following characteristics of the primary tumour were analyzed:
anatomical localization (axial vs. extremities, or unknown prima-
ry), Breslow’s tumour thickness, Clark’s level of invasion,
ulceration, histopathological subtype (superficial spreading mela-
noma [SSM] vs. nodular melanoma [NM] vs. lentigo maligna
melanoma [LMM] vs. acral lentiginous melanoma [ALM]). At the
time of start of systemic treatment the following variables were
evaluated: age, site of visceral involvement (soft tissue metastasis
vs. pulmonary involvement vs. other visceral sites), serum LDH
(normal vs..upper limit of normal [ULN]) and S100B (normal vs.
.ULN). S100B was detected using the Sangtec S100 ELISA
(Diasorin Inc., Stillwater, USA; ULN=0.15 mg/l) until December
2003 and thereafter by the Elecsys S100 electrochemilumines-
cence immunoassay (Roche Diagnostics AG, Rotkreuz, Switzer-
land, ULN=0.10 mg/l) according to the instructions of the
manufacturers. The treatment was categorized as either mono-
chemotherapy, polychemotherapy (any combination regimen
including at least 2 cytotoxic drugs), immunotherapy, biochem-
otherapy (combination of chemotherapy and immunotherapy), or
others (not assignable to any of the listed categories).
Statistical analysis
The categorization of the body site und tumor thickness of the
primary melanoma was performed as described before by studies
based on the AJCC database [16]. Categorized variables were
dummy coded to adhere to the linearity assumption of multivar-
iable regression analysis. Follow-up time was defined from the start
of systemic treatment to the date of last follow-up or death.
Estimates of cumulative survival probabilities according to
Kaplan-Meier were described together with 95% confidence
intervals (CIs) and compared using two-sided log-rank test
statistics. Median survival times (MST) are presented. For the
analysis of overall survival patients who were alive at the last
follow-up were censored, while patients who had died were
considered an ‘‘event’’.
Multivariable Cox proportional hazard models were used to
determine independent prognostic factors. Patients with missing
values were excluded from multivariable testing. Proportional
hazard assumptions were checked graphically plotting the log(-
log(survival)) versus the log of survival time. Models were initially
built as hierarchical structures including interactions; although no
interaction term was found statistically significant. Models were
compared using the Chi-square distributed differences of the log
likelihood of each model. Forward and backward stepwise
procedures of the multivariable modelling process were conducted.
Results of the Cox models were described by means of hazard
ratios together with 95% CIs, p-values were based on the Wald
test.
Confounding was assessed by checking the effect of each
remaining non-significant variable, which was not in a model, on
factors in the model. If changes in the estimate of factors in the
model of 5% or more occurred the variable was considered a
confounder. Throughout the analysis, p values less than 0.05 were
considered as statistically significant. All statistical analyses were




Patients’ characteristics are shown in Table 1. A total of 499
patients (58.5% male) were included in the survival analysis at the
start of the first systemic treatment for non-resectable stage IV
melanoma. The median age was 60 years (inter quartile range
[IQR] 49–70 years). The median follow-up for patients who died
was 10 months and 27 months for patients who were alive at the
last date of observation. The median survival time according to
Kaplan Meier (MST) was 9 months. Cumulative survival rates
were 40.0% (1-year), 15.9% (2-years), and 6.2% (5-years). Based
on the site of distant metastases the assignment to the M category
was M1c in 65.9%, M1b in 23.6% and M1a in 10.4% of patients.
109 patients (21.8%) had brain metastases. An elevated S100B or
LDH serum level was observed in 69.2% and 40.0%, respectively.
The first systemic therapy was a monochemotherapy in the
majority of patients (58.9%), a biochemotherapy, polychemother-
apy or immunotherapy was applied in 18.0%, 16.6%, and 6.5% of
patients.
Survival analysis according to Kaplan-Meier
Both factors considered in the AJCC-staging system for patients
with distant metastasis (site of distant metastases and LDH) were
strongly correlated with survival before receiving the first systemic
therapy. If distant lesions were limited to soft tissue or the lung
MST was 13 or 12 months, respectively, while it was shorter for
patients with other visceral lesions (8 months; p,0.001; Figure 1A).
The probability to be alive one year after start of systemic
treatment was twice as high for patients without cerebral
involvement compared to those with brain metastasis (44.9 vs.
Prognostic Factors at Start of First Line Therapy
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Table 1. Descriptive statistics and survival rates according to Kaplan-Meier.
Prognostic factor n % % dead
1-year survival rate [95-
CI#] (%)
2-years survival rate [95-
CI#] (%) p*
Sex Male 292 58.5 91.1 38.0 32.3 43.6 13.7 9.6 17.8 0.188
Female 207 41.5 89.9 42.8 35.9 49.6 19.0 13.5 24.5
Age at time of systemic
therapy
,50 years 128 25.7 92.2 40.4 31.7 49.0 14.8 8.5 21.1 0.914
50–59 years 117 23.4 89.7 38.5 29.5 47.5 14.5 7.8 21.2
60–69 years 128 25.7 91.4 39.4 31.0 47.8 16.4 9.9 22.9
$70 years 126 25.3 88.9 41.6 33.0 50.2 17.8 10.9 24.7
Primary tumor Occult primary 98 19.6 91.8 44.3 34.5 54.1 13.9 6.8 21.0 0.790
Apparent 401 80.4 90.3 39.2 34.3 44.1 16.4 12.7 20.1
Body site of primary Axial 234 58.4 91.0 37.5 31.2 43.8 16.0 11.3 20.7 0.435
Extremities 167 41.6 89.2 41.5 34.1 49.0 16.9 11.2 22.6
Missing 98 91.8 43.4 33.6 53.2 13.9 6.8 21.0
Histologic subtype of
primary
SSM 176 51.5 90.3 37.3 30.1 44.6 17.0 11.3 22.7 0.597
Nodular 107 31.3 89.7 42.3 32.9 51.7 18.6 11.0 26.2
LMM 16 4.7 93.8 31.3 8.6 54.0 12.5 0 28.8
ALM 43 12.6 93.0 50.4 35.3 65.5 14.4 3.8 25.0
Missing data 157 90.4 39.4 31.8 47.0 13.5 8.0 19.0
Breslow’s thickness of
primary
#1 mm 61 15.9 93.4 30.1 18.5 41.7 7.1 0.4 13.8 0.157
1.01–2 mm 108 28.2 88.9 31.6 22.8 40.4 16.1 9.0 23.2
2.01–4 mm 116 30.3 91.4 46.4 37.4 55.4 19.2 12.0 26.5
.4 mm 98 25.6 89.8 44.5 34.7 54.3 19.0 11.2 26.8
Missing data 116 90.5 42.6 33.6 51.6 14.4 7.7 21.1
Ulzeration of primary Yes 160 47.5 89.4 41.3 33.7 48.9 16.7 10.8 22.6 0.706
No 177 52.5 89.8 40.2 33.0 47.5 19.4 13.5 25.3
Missing data 162 92.6 38.5 31.1 46.0 11.0 6.1 15.9
Clark’s level of invasion Level I–III 65 20.3 90.8 30.8 19.6 42.0 13.7 5.3 22.1 0.422
Level IV 212 66.3 91.5 39.6 32.9 46.3 17.0 11.9 22.1
Level V 43 13.4 83.7 43.3 28.4 58.2 19.2 7.2 31.2
Missing data 179 91.1 43.1 35.9 50.4 14.7 9.4 20.0
Site of distant metastasis Soft tissue only 52 10.4 84.6 54.8 41.1 68.5 24.2 12.2 36.2 ,0.001
Lung 118 23.6 93.2 53.4 44.4 62.4 20.9 13.5 28.4
Other visceral 329 65.9 90.6 32.8 27.7 37.9 12.8 9.1 16.5
Presence of brain
metastases
No 390 78.2 89.0 44.9 40.0 49.8 18.5 14.6 22.4 ,0.001
Yes 109 21.8 96.3 22.5 14.7 30.3 6.6 1.9 11.3
LDH Elevated 175 40.0 93.1 20.1 14.0 26.2 6.9 3.0 10.8 ,0.001
Normal 263 60.0 87.5 50.6 44.5 56.7 21.3 16.2 26.4
Missing 61 96.7 50.8 38.3 63.3 18.0 8.4 27.6
S100B Elevated 279 69.2 93.5 30.3 24.8 35.8 8.9 5.4 12.4 ,0.001
Normal 124 30.8 84.7 52.7 43.9 61.5 25.3 17.5 33.1
Missing 96 90.8 51.6 41.6 61.6 23.7 15.1 32.3
First systemic therapy Monochemotherapy 291 58.9 90.4 41.4 35.7 47.1 15.9 11.6 20.2 ,0.001
Polychemotherapy 82 16.6 98.8 19.5 10.9 28.1 3.7 0 7.8
Immuntherapy 32 6.5 84.4 46.9 29.7 64.2 25.0 9.9 40.1
Biochemotherapy 89 18.0 86.5 51.2 40.8 61.6 24.6 15.6 33.6
Other or missing data 5
#95%-CI: 95% confidence interval;
*two-sided log-rank excluding missings.
doi:10.1371/journal.pone.0081624.t001
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22.5; log rank p,0.001; Figure 1B). Both analysed serum markers
were significantly (each log rank p,0.001) associated with survival
(Figure 1C, 1D). In patients with an elevated LDH levels MST was
5 months, representing the most powerful indicator for poor MST
among all analysed factors. Differences in prognosis were likewise
observed according to the type of treatment, with poorest MST of
6 months in patients receiving polychemotherapy and favourable
MST of 12 months for those treated with biochemotherapy.
Immunotherapy was associated with a MST of 9 months but the
chance for long term benefit was highest for those patients with a
probability of 15.6% to survive 5 years or longer (Figure 1E). No
differences in prognosis were evident for age, gender, or
histopathological characteristics of the primary melanoma. An
overview over one- and two-year survival rates is presented in
Table 1.
Multivariable Cox Proportional Hazard Analysis
Three different approaches of multivariate testing were
performed to compare the relative impact of prognostic factors
(Table 2).
First, we aimed to focus on the prognostic factors considered in
the AJCC staging classification. The treatment category, S100B
and presence of brain metastases were therefore not considered in
the first model. As expected, the site of distant metastases and
LDH, had both independent impact on prognosis. An elevated
LDH and the presence of visceral metastases other than lung and/
or soft-tissue increased the risk to die from disease by 2.1 [1.7–
2.6];p,0.001 or 1.5 [1.1–2.1];p = 0.021, respectively.
In the second model S100B and the presence of brain
metastases were likewise considered. We observed an independent
impact of S100B on prognosis (HR1.6 [1.2–2.1]; p,0.001) in
addition to LDH (HR 1.7 [1.4–2.2]; p,0.001). Interestingly, the
presence of brain metastases was more decisive for prognosis
compared to the pattern of visceral distant metastasis according to
AJCC in this model. CNS involvement independently increased
the risk of death from melanoma by 1.6-fold [1.2–2.1];p = 0.001 in
addition to the above mentioned serum markers, while the pattern
of visceral involvement according to AJCC lost its significance and
no longer represented an independent prognostic factor.
Finally, the treatment category was introduced in a third model.
In the multivariate analysis no additional prognostic impact was
observed according to the kind of treatment, while all other factors
basically remained unchanged. In propensity modelling consider-
ing all confounding variables of model 3 (M category, LDH,
presence of brain metastasis and type of treatment) a small
adjustment of the hazard ratio for patients with elevated S100B
serum levels was observed (adjusted HR 1.5 [1.2–1.9]; p = 0.002).
Bootstrapping based on 1000 bootstrapping samples was per-
formed to assess the generalizability of model 3 and showed a high
level of internal validity (data not shown).
The independent negative impact of the presence of brain
metastases, an elevated LDH and an elevated S100B observed in
the second and third model was evident by stratifying patients
according to the number of applicable unfavourable factors out of
those three. We observed MSTs of 14 months in case of none, in
contrast to 11, 6, and 4 months for patients with one, two, or all
three factors applying (log rank p,0.001; Figure 1F).
Discussion
In our analysis of 499 advanced melanoma patients with
unresectable disease we found an independent prognostic impact
of the S100B serum concentration in addition to the serum LDH.
Furthermore, S100B was the best predictor for long-term survival.
Five other studies compared both markers using multivariate
analysis in patients receiving subsequent systemic treatment [10–
14]. Deichmann et al also included a subset of patients who had
subsequent surgery [14]. Both serum markers were significantly
associated with survival in univariate analysis in all five studies.
However, according to multivariate analyses, only either LDH or
S100B remained a significant independent prognostic factor.
S100B was superior compared to LDH in the studies of Egberts et
al [10,11], while the opposite was true in the other analyses [12–
14]. Conflicting results might be caused by the low patient
numbers between 61 and 145 in the above mentioned studies. The
fact that in all studies only a single factor remained independently
significant after multivariate analysis suggests a high degree of
correlation between both serum markers.
In our analysis of 499 patients, which represent the thus far
largest cohort of unresectable patients analysed for both serum
markers, we surprisingly observed a substantial proportion of
patients with discordant elevation of the serum markers. In 33.2%
of patients with both markers available only S100B was elevated,
and 3.7% had an isolated increase of LDH. The independent
impact of both markers according to the multivariate analysis
observed in our study can therefore be explained by the
differential elevation of LDH and S100B in 36.9% of patients.
Many differences between both markers regarding tissue
expression, biological function and others might also explain their
differential increase observed in our patients. LDH is ubiquitously
expressed in different tissues and elevated serum levels are mainly
based on cell lysis. Elevation of serum LDH occurs in different
types of cancer and is associated with high tumour burden, high
cell turn-over of tumour cells or cell hypoxia-induced necrosis in
fast growing metastasis. [7,17,18] An elevated serum level is an
unspecific condition, which also occurs in many other - not cancer-
related - inflammatory disorders, after physical tissue injury or
after hypoxia-induced cell death (e.g. myocardial infarction). In
contrast, S100B is relatively tissue specific and expressed in certain
normal cells, most of which are originally derived from the neural
crest, e.g. glial cells of the brain, melanocytes and chondrocytes. In
addition, the corresponding cancer cells usually express S100B.
S100B interacts with p53 and activates STK38/NDR1, being
involved in cell survival and proliferation [19,20] suggesting a
functional capacity in cancer cells. It can be actively secreted [21]
and is likewise elevated in patients without explicit cell turnover or
damage like schizophrenia or depression [22]. These differences in
the biology between S100B and LDH may explain the differential
increase of serum levels in our patients and their independent
prognostic impact.
Interestingly, the time point of analysis of prognostic factors in
the course of disease seems to be important even after initial
occurrence of distant metastases. In fact, the rate of elevated serum
levels was increased in our patients receiving systemic treatments
compared to patients at initial stage IV disease [3]. In this study,
S100B serum levels were increased in 69% while this was only the
case in 55% of patients after occurrence of the first distant
metastasis. The relative increase was even more prominent for
LDH with 40% in our study compared to 28% reported previously
[3]. These variations during stage IV disease might explain, why
S100B was shown to be superior compared to LDH to predict
prognosis at earlier time-points, e.g. at the time of stage IV
diagnosis or before metastasectomy of distant metastasis [3,23,24],
while increasing impact is observed for LDH at later time-points
e.g. at start of systemic treatment [12–14].
We additionally analysed the outcome according to the type of
treatment. Even if differences in survival were detectable in
univariate analysis, an independent effect was no longer observed
Prognostic Factors at Start of First Line Therapy
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applying multivariate testing. This is in agreement with a meta-
analysis of 41 RTCs which showed no differences in survival
comparing monochemotherapy, polychemotherapy, immunother-
apy, and biochemotherapy [4]. This missing independent effect of
different types of therapies if its relative impact is compared to
other prognostic factors was not surprising because a high degree
of selection bias has to be assumed. According to institutional and
national guidelines patients receiving polychemotherapy were
those with high tumor load or dynamic progression. In contrast,
immunotherapies and biochemotherapies were mainly applied
within clinical trials which often excluded patients with brain
metastases or elevated LDH and therefore represent a cohort with
a better a priori prognosis. Our finding is also in agreement with
the fact, that until 2010 no systemic treatment showed an overall
survival benefit in phase 3 RTCs. The situation changed after
ipilimumab and vemurafenib became available. Both drugs
improve overall survival, but nevertheless the clinical benefit is
restricted to a small subset of patients for ipilimumab [25,26] and
it is questionable whether long-term survival can be induced by
BRAF- or MEK inhibitors [27,28]. In our study, the S100B serum
Figure 1. Univariate analysis of 499 patients. Kaplan Meier survival curves according to (A) the site of distant metastasis, (B) the presence of
brain metastases, (C) the LDH serum level, (D) the S100B serum level, (E) the type of treatment, and (F) the number of applicable unfavourable
independent prognostic factors according to the multivariate analysis (S100B, LDH, presence of brain metastasis). Censored events are indicated by
vertical lines.
doi:10.1371/journal.pone.0081624.g001
Prognostic Factors at Start of First Line Therapy
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e81624
level was stronger associated with long-term survival compared to
the LDH serum level and the presence of brain metastases, both of
which were other independent prognostic factors. Our observa-
tions provide a rationale to analyze the prognostic impact of
S100B serum levels in patients treated with BRAF- or MEK
inhibitors or by immune-checkpoint blockade and to investigate its
role to select patients for these new therapeutic options. The
observation of normal serum levels for both markers in patients
who are in need for systemic therapy could be of clinical value
especially in those with BRAF V600-mutant melanoma. In these
patients, it might be beneficial to postpone treatment with
vemurafenib or MEK-inhibitors and initially start with immuno-
therapy. Immunotherapy is characterized by longer treatment
durations to achieve clinical responses as compared to inhibitor
treatments. But also in BRAF V600 wild-type melanoma
immunotherapy might be preferred compared to (poly-)chemo-
therapy as a first line treatment in patients with both markers
within the normal range.
In conclusion, the S100B serum level predicts overall survival in
unresectable melanoma patients receiving systemic treatment. Its
relative impact is similar to LDH serum levels and the presence of
brain metastases, both of which represented additional indepen-
dent prognostic factors. Among those, S100B is most appropriate
to predict long-term survival. The type of treatment applied
Table 2. Multivariate analysis for disease-specific death.
Prognostic factor Sample size % Dead Relative risk (95% CI)# p-value
Model 1 (n=438) *
M category
M1a 44 (10.0%) 84.1% 1
M1b 97 (22.1%) 91.8% 1.2 (0.83, 1.8) P = 0.324
M1c 297 (67.8%) 89.9% 1.5 (1.1, 2.1) P = 0.021
Lactate Dehydrogenase
Normal 263 (60.0%) 87.5% 1
Elevated 175 (40.0%) 93.1% 2.1 (1.7, 2.6) P,0.001
Model 2 (n=377) **
Lactate Dehydrogenase
Normal 228 (60.5%) 88.2% 1
Elevated 149 (39.5%) 93.3% 1.7 (1.4, 2.2) P,0.001
S100B
Normal 117 (31.0%) 83.8% 1
Elevated 260 (69.0%) 93.1% 1.6 (1.2, 2.1) P,0.001
Cerebral metastases
No 293 (77.7%) 88.4% 1
Yes 84 (22.3%) 96.4% 1.6 (1.2, 2.1) P = 0.001
Model 3 (n=372) ***
Lactate Dehydrogenase
Normal 225 (60.5%) 88.0% 1
Elevated 147 (39.5%) 93.9% 1.6 (1.3, 2.1) P,0.001
S100B
Normal 116 (31.2%) 83.6% 1
Elevated 256 (68.8%) 93.4% 1.6 (1.2, 2.1) P,0.001
Cerebral metastases
No 288 (77.4%) 88.5% 1
Yes 84 (22.6%) 96.4% 1.5 (1.1, 1.9) P = 0.009
First systemic therapy
Monochemotherapy 229 (61.6%) 90.0% 1
Polychemotherapy 65 (17.5%) 100% 1.3 (0.97, 1.8) P = 0.074
Immunotherapy 24 (6.5%) 87.5% 0.81 (0.51, 1.3) P = 0.363
Biochemotherapy 54 (14.5%) 81.5% 0.75 (0.54, 1.04) P = 0.085
#95% CI = 95% confidence interval;
*61 patients had unknown values for LDH and were excluded; no confounding and no significant interaction was detected.
**122 patients had unknown values for LDH and/or S100 and were excluded; the model was adjusted for the confounding effects of M Stage IV; no significant
interaction was detected.
***127 patients had unknown values for LDH and/or S100 and/or could not be aligned to one of the 4 treatment categories and were excluded; the model was adjusted
for the confounding effects of the M category; no significant interaction was detected.
doi:10.1371/journal.pone.0081624.t002
Prognostic Factors at Start of First Line Therapy
PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e81624
between the years 2000 and 2010 did not influence prognosis. The
role of S100B to select patients for treatment and to predict
prognosis should be investigated in future studies in patients
treated with new and more potent drugs in metastatic melanoma.
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